

Lisa F Licitra

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7479322/lisa-f-licitra-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264 papers	16,717 citations	56 h-index	125 g-index
278 ext. papers	20,715 ext. citations	5.7 avg, IF	6.1 L-index

#	Paper	IF	Citations
264	Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.. <i>Future Oncology</i> , 2022 ,	3.6	2
263	When Everything Revolves Around Internal Carotid Artery: Analysis of Different Management Strategies in Patients With Very Advanced Cancer Involving the Skull Base. <i>Frontiers in Oncology</i> , 2021 , 11, 781205	5.3	
262	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. <i>European Journal of Cancer</i> , 2021 , 159, 194-204	7.5	6
261	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021 , 158, 17-26	7.5	1
260	Local therapies for liver metastases of rare head and neck cancers: a monoinstitutional case series. <i>Tumori</i> , 2021 , 107, 188-195	1.7	1
259	The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer model. <i>Cancer Causes and Control</i> , 2021 , 32, 459-471	2.8	3
258	The BURAN study of buparlisib (AN2025) in combination with paclitaxel compared to paclitaxel alone, in patients with recurrent or metastatic head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS6090-TPS6090	2.2	1
257	Next generation platinum salt in nasopharyngeal carcinoma. <i>Lancet Oncology, The</i> , 2021 , 22, 577-578	21.7	
256	Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. <i>Acta Oncologica</i> , 2021 , 60, 1192-1200	3.2	1
255	The SINTART 1 study: A phase II trial of induction chemotherapy (IC), surgery, photon-, proton-and carbon ion-based radiotherapy (RT) integration in locally advanced operable sinonasal epithelial tumors patients (pts).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6066-6066	2.2	1
254	Malignant salivary gland tumours in families with breast cancer susceptibility. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 479, 221-226	5.1	
253	Management of Salivary Gland Malignancy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1909-1941	19.1	27
252	Bleeding complications in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021 , 43, 2844-2858	4.2	3
251	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 848-857	21.7	40
250	Tipifarnib in Head and Neck Squamous Cell Carcinoma With Mutations. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1856-1864	2.2	31
249	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2359-2366	2.2	16
248	Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale. <i>Quality of Life Research</i> , 2021 , 30, 111-121	3.7	1

247	Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 171-181	9.7	12
246	Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project. <i>Head and Neck</i> , 2021 , 43, 601-612	4.2	7
245	An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma.. <i>JCO Precision Oncology</i> , 2021 , 5, 1526-1527	3.6	1
244	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100468	2.2	6
243	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. <i>European Journal of Cancer</i> , 2020 , 136, 35-42	7.5	8
242	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. <i>Cancer</i> , 2020 , 126, 1888-1894	6.4	21
241	Transcriptomics and Epigenomics in head and neck cancer: available repositories and molecular signatures. <i>Cancers of the Head & Neck</i> , 2020 , 5, 2	5.9	13
240	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	9
239	Treatment Options for Recurrent Anterior Skull Base Tumors. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 231-245	1.7	2
238	Radiotherapy and Medical Treatment 2020 , 47-56		
237	Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 518110	5.3	4
236	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. <i>Cancers</i> , 2020 , 12,	6.6	15
235	Methodology and technology for the development of a prognostic MRI-based radiomic model for the outcome of head and neck cancer patients. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2020 , 2020, 1152-1155	0.9	2
234	Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700). <i>Oncology</i> , 2020 , 98, 763-770	3.6	4
233	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , 2020 , 9,	7.9	6
232	The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 78-86	1.7	1
231	Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era. <i>Cancers</i> , 2020 , 12,	6.6	1
230	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. <i>Laryngoscope</i> , 2020 , 130, 857-865	3.6	10

229	Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy. <i>Tumori</i> , 2020 , 106, 39-46	1.7	3
228	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. <i>Oral Oncology</i> , 2019 , 97, 82-91	4.4	3
227	A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy. <i>International Journal of Medical Informatics</i> , 2019 , 129, 404-412	5.3	15
226	Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet. <i>Frontiers in Oncology</i> , 2019 , 9, 837	5.3	8
225	Systemic Therapy in Salivary Gland Carcinoma 2019 , 213-224		
224	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019 , 46, 507-514	1.6	4
223	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 435-443	5.9	5
222	Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040) 2019 , 7, 96		20
221	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , 2019 , 90, 94-101	4.4	7
220	Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. <i>Frontiers in Oncology</i> , 2019 , 9, 1522	5.3	4
219	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. <i>Dysphagia</i> , 2019 , 34, 52-62	3.7	5
218	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) 2019 , 7, 184		223
217	Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. <i>Otolaryngology - Head and Neck Surgery</i> , 2019 , 161, 635-642	5.5	12
216	The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions. <i>Frontiers in Oncology</i> , 2019 , 9, 668	5.3	21
215	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. <i>Oral Oncology</i> , 2019 , 96, 7-14	4.4	23
214	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	12
213	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. <i>Head and Neck</i> , 2019 , 41, 3670-3676	4.2	12
212	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019 , 25, 5221-5230	12.9	74

211	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019 , 125, 3208-3218	6.4	44
210	Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. <i>Clinical Therapeutics</i> , 2019 , 41, 2517-2528.e28	3.5	1
209	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 394, 1915-1928	4.0	839
208	PD-1 immunotherapy for recurrent or metastatic HNSCC. <i>Lancet, The</i> , 2019 , 394, 1882-1884	4.0	5
207	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019 , 123, 138-145	7.5	9
206	International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV. <i>Head and Neck</i> , 2019 , 41, 1725-1737	4.3	36
205	Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. <i>Radiologia Medica</i> , 2019 , 124, 414-421	6.5	13
204	Data Set for the Reporting of Carcinomas of the Nasal Cavity and Paranasal Sinuses: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting. <i>Archives of Pathology and Laboratory Medicine</i> , 2019 , 143, 424-431	5	3
203	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 393, 156-167	4.0	674
202	Treatment challenges in and outside a network setting: Head and neck cancers. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 40-45	3.6	21
201	Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel. <i>Tumori</i> , 2019 , 300891619868289 ^O	1.7	289
200	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018 , 81, 45-51	4.4	372
199	Immunotherapy for recurrent/metastatic head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2018 , 26, 152-156	2	11
198	Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience. <i>Targeted Oncology</i> , 2018 , 13, 253-256	5	8
197	Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. <i>Endocrine-Related Cancer</i> , 2018 , 25, 217-231	5.7	32
196	Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. <i>Tumori</i> , 2018 , 104, 213-220	1.7	2
195	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , 2018 , 65, 78-86	14.4	24
194	Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. <i>Cancer Treatment Reviews</i> , 2018 , 69, 164-176	14.4	21

193	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. <i>European Journal of Cancer</i> , 2018 , 93, 89-98	7.5	7
192	Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. <i>Clinical and Translational Radiation Oncology</i> , 2018 , 12, 47-52	4.6	8
191	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018 , 23, 1079-1082	5.7	44
190	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. <i>Oral Oncology</i> , 2018 , 82, 144-151	4.4	11
189	Personalized Medicine and the Contradictions and Limits of First-Generation Deescalation Trials in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018 , 144, 99-100	3.9	6
188	Different View on Larynx Preservation Evidence-Based Treatment Recommendations. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1376-1377	2.2	10
187	Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. <i>Head and Neck</i> , 2018 , 40, 2648-2656	4.2	6
186	New Data on Systemic Therapy of Salivary Gland Tumors 2018 , 277-284		
185	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. <i>Oral Oncology</i> , 2018 , 86, 266-272	4.4	17
184	Big Data in Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 62	5.4	22
183	Lung metastasectomy in adenoid cystic cancer: Is it worth it?. <i>Oral Oncology</i> , 2017 , 65, 114-118	4.4	39
182	Immunohistochemical and molecular profile of salivary gland cancer in children. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26468	3	12
181	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , 2017 , 18, 323-335	21.7	133
180	Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. <i>Oral Oncology</i> , 2017 , 66, 58-63	4.4	70
179	The EORTC module for quality of life in patients with thyroid cancer: phase III. <i>Endocrine-Related Cancer</i> , 2017 , 24, 197-207	5.7	19
178	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. <i>Oral Oncology</i> , 2017 , 69, 33-37	4.4	14
177	Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. <i>Value in Health</i> , 2017 , 20, 799-808	3.3	7
176	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2017 , 28, 2820-2826	10.3	39

175	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. <i>Disease Markers</i> , 2017 , 2017, 6870614	3.2	2
174	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1104-1115	21.7	232
173	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. <i>Oncologist</i> , 2017 , 22, 1056-1066	5.7	80
172	Benefits and Risks of Machine Learning Decision Support Systems. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 2354	27.4	7
171	Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. <i>Genes</i> , 2017 , 8,	4.2	21
170	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2017 , 7, 72	5.3	86
169	Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. <i>Oncotarget</i> , 2017 , 8, 47780-47789	3.3	22
168	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 44-53	12.9	152
167	Long-term update of the 24954 EORTC phase III trial on larynx preservation. <i>European Journal of Cancer</i> , 2016 , 65, 109-12	7.5	26
166	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. <i>Oncologist</i> , 2016 , 21, 1218-1229	5.7	86
165	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 959-966	4	28
164	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016 , 69, 158-165	7.5	44
163	Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM. <i>Medical Oncology</i> , 2016 , 33, 76	3.7	4
162	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016 , 22, 3961-70	12.9	53
161	Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. <i>Annals of Oncology</i> , 2016 , 27, 1585-93	10.3	33
160	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. <i>Head and Neck</i> , 2016 , 38, 724-31	4.2	82
159	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 57-75	5.5	39
158	Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 100-6	7	45

157	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. <i>Oral Oncology</i> , 2016 , 54, 54-7	4.4	39
156	Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2016 , 52, 18-23	4.4	19
155	Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 74362-74379	3.3	104
154	Management of Salivary Gland Cancer 2016 , 625-640		
153	Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report. <i>Tumori</i> , 2016 , 102,	1.7	1
152	Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E1521472	4.7	18
151	Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E1009-13	4.2	5
150	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. <i>Oral Oncology</i> , 2016 , 58, e4-5	4.4	2
149	Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study. <i>Thyroid</i> , 2016 , 26, 1605-1613	6.2	25
148	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 67, 174-182	7.5	46
147	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016 , 375, 1856-1867	59.2	2647
146	Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer. <i>Oral Oncology</i> , 2016 , 59, 73-79	4.4	61
145	Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015 , 75, 1205-15	10.1	63
144	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 167-82	7	39
143	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 372-84	7	75
142	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. <i>Annals of Oncology</i> , 2015 , 26, 300-6	10.3	51
141	Italian version of the M.D. Anderson Symptom Inventory--Head and Neck Module: linguistic validation. <i>Supportive Care in Cancer</i> , 2015 , 23, 3465-72	3.9	6
140	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 583-94	21.7	293

139	Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. <i>Annals of Oncology</i> , 2015 , 26, 1248-1253	10.3	19
138	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EURO-CARE-5 population-based study. <i>European Journal of Cancer</i> , 2015 , 51, 2130-2143	7.5	250
137	Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 2596-603	7.5	44
136	Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base'. <i>British Journal of Cancer</i> , 2015 , 113, 1638-9	8.7	
135	Smoothed (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. <i>Molecular Oncology</i> , 2015 , 9, 389-97	7.9	103
134	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2015 , 44, 734-45	3.3	6
133	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. <i>Cancer</i> , 2015 , 121, 2749-56	6.4	130
132	Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III. <i>Head and Neck</i> , 2015 , 37, 1358-67	4.2	44
131	Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?. <i>Journal of Oral Pathology and Medicine</i> , 2015 , 44, 728-33	3.3	3
130	Hope in cancer patients: the relational domain as a crucial factor. <i>Tumori</i> , 2015 , 101, 447-54	1.7	19
129	Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. <i>Future Oncology</i> , 2015 , 11, 1429-35	3.6	7
128	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 191-213	7	28
127	Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. <i>Future Oncology</i> , 2015 , 11, 703-12	3.6	25
126	Vismodegib in patients with advanced basal cell carcinoma (STEVE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncology</i> , 2015 , 16, 729-36	21.7	161
125	Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015 , 51, 271-81	7.5	80
124	Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. <i>Cancer Letters</i> , 2015 , 359, 269-74	9.9	8
123	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. <i>Oncotarget</i> , 2015 , 6, 9627-42	3.3	79
122	An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 1227-39	3.5	62

121	Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. <i>Annals of Oncology</i> , 2014 , 25, 801-807	10.3	159
120	Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. <i>Annals of Oncology</i> , 2014 , 25, 1628-35	10.3	39
119	Antiangiogenic TKIs and advanced RAI-resistant thyroid cancer: time for rethinking treatment strategies?. <i>Thyroid</i> , 2014 , 24, 1815	6.2	3
118	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. <i>Annals of Oncology</i> , 2014 , 25, 462-6	10.3	58
117	Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. <i>Oral Oncology</i> , 2014 , 50, 884-7	4.4	14
116	Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. <i>BMC Cancer</i> , 2014 , 14, 473	4.8	17
115	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014 , 25, 694-699	10.3	27
114	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. <i>Cancer</i> , 2014 , 120, 2694-703	6.4	81
113	Best practices in the management of the psycho-oncologic aspects of head and neck cancer patients: recommendations from the European Head and Neck Cancer Society Make Sense Campaign. <i>Annals of Oncology</i> , 2014 , 25, 2115-2124	10.3	38
112	Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. <i>Future Oncology</i> , 2014 , 10, 2111-20	3.6	3
111	Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. <i>Clinical Cancer Research</i> , 2014 , 20, 6570-81	12.9	55
110	Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. <i>Cancer Epidemiology</i> , 2014 , 38, 670-8	2.8	24
109	An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group. <i>Cancer</i> , 2014 , 120, 390-8	6.4	30
108	Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. <i>Radiotherapy and Oncology</i> , 2014 , 113, 260-6	5.3	20
107	Fosbretabulin for the treatment of anaplastic thyroid cancer. <i>Future Oncology</i> , 2014 , 10, 2015-21	3.6	10
106	Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. <i>Cancer Biology and Therapy</i> , 2014 , 15, 678-82	4.6	17
105	Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. <i>Thyroid</i> , 2014 , 24, 232-40	6.2	108
104	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. <i>European Journal of Cancer</i> , 2013 , 49, 1161-8	7.5	128

103	Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2013 , 49, 2877-83	7.5	25
102	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013 , 49, 413-9	4.4	32
101	Salivary gland cancer: an update on present and emerging therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 257-63	7.1	18
100	RET inhibition: implications in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 403-19	6.4	36
99	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. <i>Lancet Oncology</i> , 2013 , 14, 697-710	21.7	343
98	Comments on "postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure" by Chan and Coll. <i>Oral Oncology</i> , 2013 , 49, e38	4.4	1
97	Cabozantinib in progressive medullary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3639-46	2.2	762
96	Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>Future Oncology</i> , 2013 , 9, 103-14	3.6	23
95	Emerging tyrosine kinase inhibitors for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 445-59	3.7	6
94	Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. <i>Current Opinion in Oncology</i> , 2013 , 25, 224-8	4.2	27
93	Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2013 , 35, 1471-4	4.2	13
92	Salivary Gland Cancer: An Update on Present and Emerging Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 257-263	7.1	24
91	Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6027-6027	2.2	2
90	Management of salivary gland tumors. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1161-8	3.5	47
89	Carcinoma anaplastico della tiroide. <i>L Endocrinologo</i> , 2012 , 13, 216-220	0	
88	Rare cancers of the head and neck area in Europe. <i>European Journal of Cancer</i> , 2012 , 48, 783-96	7.5	44
87	From chemoprevention and organ preservation programs to post-operative management: major achievements and strategies of the EORTC Head and Neck Cancer Group. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 76-81	1.6	
86	Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, e226-8	4.5	7

85	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. <i>Cancer</i> , 2012 , 118, 4694-705	6.4	34
84	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. <i>Annals of Oncology</i> , 2012 , 23, 435-41	10.3	42
83	Oropharyngeal cancer - is it time to change management according to human papilloma virus status?. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2012 , 20, 120-4	2	42
82	Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. <i>Annals of Oncology</i> , 2012 , 23, 1825-32	10.3	17
81	How many therapeutic options are there for recurrent or metastatic salivary duct carcinoma?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 672; author reply 672-673	2.2	4
80	Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile. <i>Journal of Clinical Oncology</i> , 2012 , 30, 564-5; 565-567	2.2	16
79	Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii83-5	10.3	149
78	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012 , 23, 1832-7	10.3	82
77	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5508-5508	2.2	54
76	Rare cancers are not so rare: the rare cancer burden in Europe. <i>European Journal of Cancer</i> , 2011 , 47, 2493-511	7.5	398
75	Targeted therapy in head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2011 , 19, 132-7	2	9
74	Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 774-7; author reply 777-8	6.7	56
73	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. <i>Annals of Oncology</i> , 2011 , 22, 1078-1087	10.3	182
72	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 1886-93	10.3	19
71	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. <i>Annals of Oncology</i> , 2011 , 22, 2495-2500	10.3	25
70	Management of Salivary Gland Cancer 2011 , 521-532		
69	Tumori maligni epiteliali dell'orofaringe 2011 , 309-319		
68	Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v184-6	10.3	391

67	TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 761-6	2.2	92
66	Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. <i>Annals of Oncology</i> , 2010 , 21, 1952-1960	10.3	19
65	Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v187-9	10.3	36
64	Multikinase inhibitors in thyroid cancer. <i>European Journal of Cancer</i> , 2010 , 46, 1012-8	7.5	13
63	Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis", by Rades et coll. <i>Oral Oncology</i> , 2010 , 46, 888; author reply 889-90	4.4	
62	Major and minor salivary gland tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 134-48	7	254
61	Head and neck cancer. <i>Journal of Oncology</i> , 2009 , 2009, 358098	4.5	1
60	Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 142-52	9.7	215
59	Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009 , 20 Suppl 4, 121-2	10.3	50
58	Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1864-71	2.2	303
57	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009 , 45, 574-8	4.4	150
56	Survival from salivary glands adenoid cystic carcinoma in European populations. <i>Oral Oncology</i> , 2009 , 45, 669-74	4.4	72
55	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). <i>Oral Oncology</i> , 2009 , 45, 986-90	4.4	111
54	Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 774-80	4	33
53	Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 1053-9	4	32
52	TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. <i>Translational Oncology</i> , 2008 , 1, 121-8	4.9	14
51	Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). <i>European Journal of Cancer</i> , 2008 , 44, 2542-5	7.5	46
50	Human papillomavirus in HNSCC: a European epidemiologic perspective. <i>Hematology/Oncology Clinics of North America</i> , 2008 , 22, 1143-53, vii-viii	3.1	34

49	Motesanib diphosphate in progressive differentiated thyroid cancer. <i>New England Journal of Medicine</i> , 2008 , 359, 31-42	59.2	397
48	Folate in head and neck squamous cell cancer chemoprevention: purposely left out?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3463; author reply 3463-4	2.2	2
47	Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii200-3	10.3	16
46	TP53 mutations in head and neck cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 1194; author reply 1195	59.2	1
45	Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 70, 330-7	4	41
44	p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. <i>Cancer</i> , 2007 , 109, 2461-5	6.4	28
43	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. <i>Annals of Oncology</i> , 2007 , 18, 601-2	10.3	22
42	Biological agents in head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1643-50	3.5	4
41	Biological agents in head and neck cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 10, x45-8	10.3	3
40	High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5630-6	2.2	531
39	Systemic therapy in the palliative management of advanced salivary gland cancers. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2673-8	2.2	223
38	Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>Head and Neck</i> , 2006 , 28, 909-15	4.2	29
37	Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2006 , 12, 6643-51	12.9	133
36	A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?. <i>Current Opinion in Oncology</i> , 2006 , 18, 253-7	4.2	20
35	Advances in the changing patterns of aetiology of head and neck cancers. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2006 , 14, 95-9	2	7
34	Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas?. <i>Oral Oncology</i> , 2005 , 41, 219-221		
33	Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. <i>Oral Oncology</i> , 2005 , 41, 97-8	4.4	17
32	Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. <i>Oral Oncology</i> , 2005 , 41, 890-4.	4.4	42

31	Which classification for ethmoid malignant tumors involving the anterior skull base?. <i>Head and Neck</i> , 2005 , 27, 224-31	4.2	19
30	Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7757-8; author reply 7758-9	2.2	5
29	Is there still a role for neoadjuvant chemotherapy in head and neck cancer?. <i>Annals of Oncology</i> , 2004 , 15, 7-11	10.3	24
28	Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4901-6	2.2	86
27	Head and neck tumors other than squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2004 , 16, 236-41	4.2	15
26	Chemoradiation therapy in locally advanced nasopharyngeal cancer: which kind of cooperation?. <i>Annals of Oncology</i> , 2003 , 14, 508-9	10.3	3
25	TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>International Journal of Cancer</i> , 2003 , 105, 196-203	7.5	79
24	Cancer of the nasopharynx. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 45, 199-213	7	45
23	Major and minor salivary glands tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 45, 215-25	7	60
22	Cancer of the larynx. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 47, 65-80	7	76
21	Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma. <i>Clinical Oncology</i> , 2003 , 15, 451-60	2.8	13
20	A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. <i>Annals of Oncology</i> , 2003 , 14, 1327-8	10.3	50
19	Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 327-33	2.2	192
18	Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. <i>Annals of Oncology</i> , 2003 , 14, 367-72	10.3	48
17	Forecasting the performance status of head and neck cancer patient treatment by an interval arithmetic pruned perceptron. <i>IEEE Transactions on Biomedical Engineering</i> , 2002 , 49, 782-7	5	9
16	Primary high-grade mucoepidermoid carcinoma of the minor salivary glands with cutaneous metastases at diagnosis. <i>Oral Oncology</i> , 2002 , 38, 401-4	4.4	14
15	Cancer of the oropharynx. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 41, 107-22	7	48
14	Cancer of the anal region. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 43, 77-92	7	20

13	Antiemetic therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 43, 93-101	7	4
12	Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). <i>Quality of Life Research</i> , 2000 , 9, 151-9	3.7	30
11	Treatment of Cancer of the Base of the Tongue and Glosso-Epiglottic Region: A Multicenter Italian Survey. <i>Tumori</i> , 2000 , 86, 215-223	1.7	2
10	START: a European state-of-the-art on-line instrument for clinical oncologists. <i>Annals of Oncology</i> , 1999 , 10, 769-73	10.3	12
9	A new classification for malignant tumors involving the anterior skull base. <i>JAMA Otolaryngology</i> , 1999 , 125, 1252-7		36
8	Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. <i>International Journal of Cancer</i> , 1998 , 79, 619-23	7.5	22
7	The Multidisciplinary Approach in Clinical Oncology. <i>Tumori</i> , 1998 , 84, 279-280	1.7	2
6	Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. <i>Annals of Oncology</i> , 1997 , 8, 1157-8	10.3	8
5	Quality of life assessment and clinical decision-making. <i>Annals of Oncology</i> , 1997 , 8, 1207-11	10.3	15
4	Salvage surgery of cervical recurrences after neck dissection or radiotherapy. <i>Head and Neck</i> , 1993 , 15, 292-5	4.2	29
3	Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. <i>Cancer</i> , 1991 , 68, 1874-7	6.4	86
2	Nasal Cavity and Paranasal Sinus 586-596		
1	Nasal cavity and paranasal sinus 586-596		1